

Sultan of Johor Announces Tunku Laksamana Johor Cancer Centre To Be Completed by 2020

Malaysia's first integrative medical unit will be built in collaboration with ASX-listed Asian American Medical Group



His Majesty Sultan Ibrahim Ibni Almarhum Sultan Iskandar, the Sultan of Johor, signing the commemorative plaque for the launch of the Tunku Laksamana Johor Cancer Centre.

Witnessed by (L to R): Yang Berhormat Dato' Azmi bin Rohani, Johor State Secretary; His Royal Highness / Duli Yang Amat Mulia Tunku Ismail ibni Sultan Ibrahim, Tunku Mahkota Johor; and Dato' Dr. Tan Kah Chai, Executive Chairman, Asian American Medical Group.

JOHOR BAHRU, 2 April 2018 – His Majesty Sultan Ibrahim Ibni Almarhum Sultan Iskandar, the Sultan of Johor, announced yesterday that an advanced cancer treatment centre would be set up in the heart of Iskandar, led by Singapore-headquartered healthcare specialist Asian American Medical Group (“AAMG”).

The Tunku Laksamana Johor Cancer Centre (“TLJCC” or the “Johor Project”) will be a private, purpose-built facility for cancer treatment, research and education. Slated to commence operations by end of 2020, Phase 1 of the project will feature state-of-the-art cancer diagnostic and treatment facilities for services such as:

- i. Advanced diagnostic and imaging services such as PET/CT (Positron Emission Tomography / Computed Tomography) and CT/MRI (Magnetic Resonance Imaging) together with liquid biopsy;
- ii. Personalised oncology using gene profiling and targeted chemo and immunotherapy; and
- iii. Specialised radiation therapy treatment such as Intensity-Modulated Radiotherapy (IMRT), Stereotactic Body Radiation Therapy (SBRT) and Volumetric Arc Therapy (VMAT).

A dedicated Integrative Medical Unit will also be set up, combining Western cancer treatment with proven traditional therapies in a closely monitored setting to provide a holistic treatment model. Some of these therapies include yoga, meditation, acupuncture and aroma/herbal therapy. His Majesty has also donated a Healing Garden for cancer patients and their families.

“Johor will be the first in Malaysia, and indeed in this region, to have such a comprehensive specialist cancer centre. This is the latest in a series of initiatives by the Johor Royal Family to bring advanced cancer treatment to Johor,” said Sultan Ibrahim at the announcement ceremony held in Persada Johor International Convention Centre yesterday.

Phase 1 of the centre, with a gross development value of RM 300 million (US\$ 77 million) and built-up area of approximately 14,000 square metres, will offer ambulatory cancer facility comprising 30 day beds. At full capacity, Phase 1 of the centre is able to treat up to 7,000 patients a year.

Phase 2 will likely include inpatient services including a Syariah-compliant women’s wing to address the special medical needs of female patients. There will also be operating rooms, a laboratory for medicine and advanced molecular diagnostics, and a medical mall with specialist retail outlets as well as offices and laboratories.

The project is about a 25-minute drive from Senai International Airport, 25 minutes from Malaysia–Singapore Second Link (also known as the Tuas Second Link) and 40 minutes from Johor–Singapore Causeway, which is connected by road and rail links to Singapore. Construction is expected to begin in Q3 2018.

Australian Securities Exchange-listed AAMG, led by Executive Chairman and renowned liver surgeon Dato’ Dr. Tan Kai Chah, has been tasked by His Majesty to develop TLJCC as a regional centre for research and education. AAMG will design and build the facility, as well as engage top medical practitioners and procure cutting-edge medical equipment.

AAMG’s current operations include Asian American Liver Centre Pte Ltd (“AALC”), one of Asia’s foremost liver centres, and Asian American Radiation & Oncology Pte Ltd (“AARO”), which offers clinical, consultancy and management services in radiation and oncology. AARO will operate TLJCC upon its completion.

TLJCC will collaborate with leading medical practitioners and institutions from around the world, including Concord Medical Services Holdings Ltd (“CCM”). CCM provides speciality hospital management solutions and operates a large network of radiotherapy and diagnostic centres. In addition, CCM has signed a series of strategic consultation agreements exclusively with The

University of Texas MD Anderson Cancer Center and will utilise this partnership to enhance services at TLJCC.

“Participation in TLJCC is an important milestone for CCM and Concord International Hospital (“CIH”), allowing us to extend our cancer care management services to the region. Being a Malaysian myself, I am grateful and excited about our strategic partnership with AAMG; bringing our best cancer care closer to home through our affiliation with one of the world’s best cancer research institutions from the United States,” said Mr. Yap Yaw Kong, Chief Financial Officer of CCM and Chairman of CIH.

TLJCC is being established in memory of Almarhum Tunku Abdul Jalil Iskandar Ibni Sultan Ibrahim, Tunku Laksamana Johor, who died from liver cancer in 2015 at age 25. The Prince was His Majesty’s third son and was known for his philanthropic nature. The centre will fulfil his dream to alleviate the suffering of fellow patients by contributing part of its annual profits to help needy cancer patients and their families.

“Tunku Jalil often went out of the way to visit, encourage and inspire other cancer patients and survivors. He promised to fight for their cause and ease the burden of cancer patients. My family and I will continue what Tunku Jalil had hoped to accomplish – to ensure that his legacy lives on,” His Majesty said.

“TLJCC will aim to set a new standard for the diagnosis and holistic treatment of cancer. AAMG is proud to collaborate with global partners to ensure that the centre offers best-in-class clinical outcomes. Apart from serving Malaysians, its close proximity to Singapore can position Johor as a leading medical destination with the best oncological care in the region,” Dato’ Dr. Tan said.

##End of Press Release##

ABOUT ASIAN AMERICAN MEDICAL GROUP

Asian American Medical Group (“AAMG”) is based in Singapore and has been listed on the Australian Securities Exchange since September 2009. The Group’s operations include the Asian American Liver Centre Pte Ltd (“AALC”), established in 1994 in Singapore, and Asian American Radiation & Oncology Pte Ltd (“AARO”).

The Group entered into a strategic collaboration in October 2012 with the US-based US\$16-billion integrated global health enterprise University of Pittsburgh Medical Center (“UPMC”). UPMC, ranked No. 14 on the U.S. News & World Report Honor Roll of American’s Best Hospitals, is affiliated with the University of Pittsburgh Schools of the Health Sciences and are pioneers in the field of transplantation. This collaboration has enhanced AAMG’s clinical capabilities through shared protocols, rigorous quality standards and technology and also created a platform for AAMG to expand into other countries in Asia such as Malaysia and Myanmar.

AALC, one of Asia's foremost liver centres, is led by renowned hepatobiliary expert and liver transplant surgeon, Dato' Dr. Tan Kai Chah (Dr. K.C. Tan), who helped start the Liver Transplant Programme at the King's College Hospital London, United Kingdom, and pioneered the highly successful Living Donor Liver Transplantation (LDLT) Programme in Singapore. In 2004, AALC began conducting surgical procedures at the IHEAL Medical Centre located in Kuala Lumpur, Malaysia.

AARO, established in March 2015, offers radiation and oncology clinical, consultancy and management services and is led by Dr. Daniel Tan Yat Harn. Based in Singapore, AARO will drive expansion into the growing radiotherapy and oncology segment in the overseas market, at a time where there is a shortage of modern radiotherapy treatment centres.

For further information, please visit: www.aamg.co

Media contact:

WeR1 Consultants Pte Ltd
3 Phillip Street, #12-01
Royal Group Building
Singapore 048693

Mr. Roshan Singh; roshansingh@wer1.net

Ms. Asha Devi; ashadevi@wer1.net

Tel: (65) 6737 4844